

Fatal Chronic Immune Thrombocytopenia with Co-existent Type-1 Neurofibromatosis

DAISY KHERA¹, SIYARAM DIDEL², ABHISHEK PUROHIT³, SWATI UMASHANKER⁴, MOHAMMED RAMZAN⁵**Keywords:** Neurofibromatosis-1, Menorrhagea, Intracranial bleed, Severe bleed

Dear Editor,

We would like to update about the follow-up outcome of the child, whose case report was published in this journal [1]. The child was previously managed by the primary unit with consultation of paediatric haematology team. A clinical diagnosis of immune thrombocytopenia with underlying neurofibromatosis was considered and she was managed with oral steroid and discharged on oral prednisolone. She responded well and her platelet count improved (Investigations dated 3rd September 2019 showed Hemoglobin (Hb), total leucocyte count and platelet count being 11.3 g/dL, $8.18 \times 10^3 \mu\text{L}$, $256 \times 10^3/\mu\text{L}$, respectively). She was discharged but she could not attend haematology clinic on follow-up due to COVID-19 related nationwide lock down. She stopped all her medication and no follow-up blood counts were available for the next 14 months. She was doing fine for nearly one year. She presented again on 27th november 2020 with menorrhagia, severe anaemia and thrombocytopenia (Hb-3.2 g/dL, total leucocyte count- $11.27 \times 10^3/\text{mL}$, platelet $2 \times 10^3/\text{mL}$). She was admitted under same primary unit and started on injection methylprednisolone 500 mg intravenous (i.v.) in view of poor response to the oral steroid therapy and persistent menorrhagia soon her condition worsened and she developed severe headache and raised Intra Cranial Pressure (ICP).

Intracranial bleed was suspected and she was shifted to paediatric haematology unit for further management and was admitted to paediatric intensive care unit. Her Non Contrast Computed Tomography (NCCT) revealed acute-on-chronic intracranial bleed along with midline shift. She was started on i.v. methylprednisolone 1 gm/day along with i.v. immunoglobulin @ 2 gm/kg over 24 hours. But her platelet did not improve over next 72 hours. Her blood group was B Rh +ve, hence she was also considered for anti-D immunoglobulin but could not be given due to its non-availability in the market [2,3]. She was also given multiple single donor platelet in view of persistent severe thrombocytopenia and persistent headache over next one week, but her platelets never crossed $10000/\mu\text{L}$ and rapidly fell down

to the range of 2000-3000 μL . She was also started on injection romiplastin for persistent thrombocytopenia. Her hepatitis B and C and Human Immunodeficiency Virus (HIV) serology was negative, Antinuclear Antibody (ANA), anti-ds Deoxyribonucleic Acid (DNA) were also negative.

Other causes like malignancy or aplastic anaemia were ruled out with bone marrow examination which was reported as hypercellular marrow with all haematopoietic components and prominence of erythroid precursors and megakaryocytes [4]. In view of persistent thrombocytopenia, she was started on azathioprine and considered for emergency splenectomy [5], but her clinical condition worsened further with recurrence of severe intracranial bleed and succumbed to her illness.

This case highlights the severe nature of the illness and the need to ensure adequate compliance and regular follow-up to avoid catastrophic complication. This case also highlights the untoward effect of COVID-19 related problem faced by patients with chronic illnesses. The association of chronic immune thrombocytopenia with type-1 neurofibromatosis is co-incidental or does it have any true association of such severe immune thrombocytopenia still need to be established.

REFERENCES

- [1] Sharma C, Bansal S, Shekhar S, Jhirwal M, Patwa P. Immune thrombocytopenia causing abnormal uterine bleeding in an adolescent girl having co-existent type-1 neurofibromatosis- is it an association or coincidence? Journal of Clinical and Diagnostic Research. 2020;14(11):QD01-QD03.
- [2] Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020;4(2):252]. Blood Adv. 2019;3(23):3829-66.
- [3] Sahi PK, Chandra J. Immune thrombocytopenia: American Society of Hematology Guidelines, 2019. Indian Pediatr. 2020;57(9):854-56.
- [4] Purohit A, Aggarwal M, Singh PK, Mahapatra M, Seth T, Tyagi S, et al. Re-evaluation of need for bone marrow examination in patients with isolated thrombocytopenia contributors [published correction appears in Indian J Hematol Blood Transfus. 2016 Jun;32(2):197]. Indian J Hematol Blood Transfus. 2016;32(2):193-96.
- [5] Singh G, Bansal D, Wright NAM. Immune thrombocytopenia in children: Consensus and controversies. Indian J Pediatr. 2020;87(2):150-57.

PARTICULARS OF CONTRIBUTORS:

1. Additional Professor, Department of Paediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
2. Assistant Professor, Department of Paediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
3. Associate Professor, Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
4. PICU Fellow, Department of Paediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
5. Senior Resident, Department of Paediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Siyaram Didel,
3091, AIIMS Medical College Building, Basni Industrial Area,
Phase-2, Jodhpur-342005, Rajasthan, India.
E-mail: drdsram2001@gmail.com

PLAGIARISM CHECKING METHODS: [Jan H et al.]

- Plagiarism X-checker: Jan 08, 2021
- Manual Googling: Feb 10, 2021
- iThenticate Software: Mar 23, 2021 (4%)

ETYMOLOGY: Author Origin

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? NA
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: **Jan 07, 2021**
Date of Peer Review: **Feb 12, 2021**
Date of Acceptance: **Feb 24, 2021**
Date of Publishing: **May 01, 2021**